|1.||Erel, Ozcan: 10 articles (09/2015 - 03/2007)|
|2.||Aksoy, Nurten: 10 articles (12/2014 - 01/2008)|
|3.||Celik, Hakim: 10 articles (10/2013 - 01/2007)|
|4.||Aslan, Mehmet: 8 articles (06/2015 - 03/2007)|
|5.||Ergin, Merve: 6 articles (08/2015 - 01/2013)|
|6.||Selek, Sahbettin: 6 articles (06/2015 - 03/2007)|
|7.||Yilmaz, Necat: 6 articles (01/2015 - 01/2013)|
|8.||Dirican, Melahat: 6 articles (09/2007 - 11/2004)|
|9.||Sánchez-Muniz, Francisco J: 5 articles (09/2015 - 09/2006)|
|10.||Aydin, Ozgur: 5 articles (01/2014 - 01/2013)|
06/01/1977 - "[Activity of arylesterase under normal conditions and in poisoning]."
04/23/2003 - "This study focused on the investigation of PON1, arylesterase and cholinesterase activities in 28 acute OP insecticide poisoning cases. "
07/20/2006 - "It is also a potent cholinesterase inhibitor and an arylesterase, combating organophosphate poisoning and metabolization of environmental neurotoxins which might be responsible for neurodegeneration with aging. "
01/01/2003 - "PON-1 is also an arylesterase that hydrolyzes paraoxon, an active toxic metabolite of parathion, thus providing protection against organophosphate poisoning and metabolization of environmental neurotoxins that might be responsible for neurodegeneration with aging. "
07/01/2013 - "The aim of this study was to investigate serum paraoxonase (PON), arylesterase (ARLY), ceruloplasmin (Cp), and myeloperoxidase (MPO) activity and lipid hydroperoxide (LOOH) and total sulfhydryl group (-SH) levels in patients with snake venom poisoning. "
11/01/2015 - "In this study we determined if inflammation leads to altered PON1 activity using three different substrate hydrolysis rates, paraoxonase (PON), arylesterase (ARE) and lactonase (LAC) in breast cancer recurrence. "
03/01/2010 - "Non-diabetic metabolic syndrome and obesity do not affect serum paraoxonase and arylesterase activities but do affect oxidative stress and inflammation."
02/01/2013 - "Endogenous anti-oxidants Paraoxonase 1 and arylesterase levels are important in evaluating the inflammation at the remission period of FMF."
07/01/2008 - "Both activities correlated with transferrin, albumin, CRP and inflammation-based Glasgow Prognostic Score, and arylesterase activity also with interleukin-6 and midkine. "
01/01/2014 - "Decreased PON1 arylesterase activity and increased VWF levels were associated with severe atherosclerosis in non-diabetic SCAD patients. "
06/01/2011 - "The aim of this study was to evaluate PON1 and arylesterase enzyme activities and lipid hydroperoxide (LOOH) levels, and to investigate whether there is increased susceptibility to atherogenesis in obese subjects, which might be reflected by increased oxidative stress and decreased PON1 activity. "
11/01/2012 - "Diminished serum paraoxonase and arylesterase activities (measures of paraoxonase-1 [PON-1] function) in humans have been linked to heightened systemic oxidative stress and atherosclerosis risk. "
06/01/2012 - "To investigate paraoxonase and arylesterase activities along with oxidative status parameters and serum lipid levels, and to find out if there is any increased susceptibility to atherogenesis. "
08/01/2009 - "BTM patients may be more prone to development of atherogenesis because of low serum paraoxonase/arylesterase activity."
01/01/2012 - "Laboratory studies included five polymorphisms of the PON1 gene (L55M, Q192R, -108C/T, -126C/T, and -162A/G), PON1 arylesterase (PON1-A) and lactonase (PON1-L) activities, as well as some markers of protein metabolism, insulin resistance, and oxidative stress. "
12/01/2014 - "The aim of this study was to determine PON1 and arylesterase (AREST) enzyme levels in relation to insulin resistance (IR) or obesity among children and adolescents. "
07/01/2013 - "The study aimed to ascertain level ranges of homocysteine (tHcyt), arylesterase (AE), lipids/lipoproteins, and insulin resistance/sensitivity markers in full-term neonates and to determine the concurrence effect of dyslipaemia and dysglycaemia on those parameters at birth. "
04/01/2011 - "In 19 nondiabetic subjects with MetS and 67 subjects without MetS, serum PON-1, assayed as its arylesterase activity, and SAA were measured together with plasma lipids and lipoproteins, high-sensitive C-reactive protein (hs-CRP) and insulin resistance (homeostasis model assessment (HOMA(ir)). "
11/01/2015 - "The serum PONI and arylesterase ARE decreased significantly in ischemic stroke patients (p<0.001). "
11/01/2015 - "Relation of Paraoxonase1, Arylesterase and Lipid Profile in Ischemic Stroke Patients."
06/01/2013 - "Stroke patients with PON1 QQ192 or MM55 genotypes demonstrated lower PON and arylesterase activities at both Day 1 and 12 months post-stroke than patients with either RQ/RR192 or LM/LL55 genotypes (P < 0.001). "
04/01/2013 - "In patients with CKD, decreased serum arylesterase activity, a measure of diminished antioxidant properties of PON-1, predicts higher risk of incident long-term adverse cardiovascular events (heart attack, stroke, or death) in multivariable models adjusting for established clinical and biochemical risk factors."
01/01/2009 - "The activity of arylesterase is modified by tobacco smoking in ischemic stroke patients. "
|3.||Oxidants (Oxidizing Agents)
|5.||Parathion (Ethyl Parathion)
|2.||Renal Dialysis (Hemodialysis)